<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119467">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02072070</url>
  </required_header>
  <id_info>
    <org_study_id>KS-TGC-01-3</org_study_id>
    <nct_id>NCT02072070</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis</brief_title>
  <official_title>A Placebo Controlled, Double-blind, Randomized, Parallel-group, Multi-center Phase III Study to Determine the Efficacy and Safety of TissueGene-C in Patients With Degenerative Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kolon Life Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kolon Life Science</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether TissueGene-C, an allogeneic human
      chondrocytes expressing TGF-b1, is effective and safe in patients with osteoarthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TissueGene-C is a biological new drug which consists of normal chondrocyte cells and
      transduced chondrocyte cells that express growth factor to modify OA symptom for long term
      period.

      During the Phase 3 clinical trial , we will compare TissueGene-C to placebo in 52 weeks
      trial with 156 outpatients who have osteoarthritis. The outpatients are randomized to
      TissueGene-C or placebo in 1:1 ratio, and they will be monitored and recorded in terms of
      alleviating symptoms, sports activities, function of the knee, and the presence of adverse
      events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changes in IKDC scores</measure>
    <time_frame>Week 0, 4, 12, 26 and 52</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in 100 mm VAS scores</measure>
    <time_frame>Week 0, 4, 12, 26 and 52</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in WOMAC scores</measure>
    <time_frame>Week 0, 4, 12, 26 and 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in KOOS scores</measure>
    <time_frame>Week 0, 4, 12, 26 and 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in MRI scan</measure>
    <time_frame>Week 0, 26 and 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Joint Space Width by an independent radiographic reviewer.</measure>
    <time_frame>Week 0, 26 and 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Biomarkers in blood and urine.</measure>
    <time_frame>Week 0, 26 and 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Use of Rescue Medication.</measure>
    <time_frame>Week 4, 12, 26 and 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Degenerative Arthritis</condition>
  <arm_group>
    <arm_group_label>TissueGene-C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intra-articular injection to the damaged knee joint at a dose of 1.8 x 10^7 cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single intra-articular injection to the damaged knee joint</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TissueGene-C</intervention_name>
    <description>Tissuege-C at 1.8 x 10^7 cells</description>
    <arm_group_label>TissueGene-C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo control(Normal Saline)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients at least 19 years of age

          -  Patients with IKDC score of 60 or below

          -  Patients with 100 mm VAS score of 40 or above

          -  Body Mass Index (BMI) between '18.5 - 30.0'

          -  Clinical diagnosis of degenerative arthritis

          -  Kellgren &amp; Lawrence Grade 3

          -  ICRS of grade â…¢ or IV, defect &lt; 6 cm2

          -  Female patients of childbearing potential must agree to practice adequate methods of
             birth control to prevent pregnancy during the study

          -  Patients who voluntarily agreed to enroll in the study and signed an informed consent
             form

        Exclusion Criteria:

          -  Patients with abnormal hematology, serum chemistry, or urinalysis screening
             laboratory results

          -  Patients taking steroidal anti-inflammatory medications within 14 days of baseline
             visit unless washed out

          -  Patients with ongoing infectious disease, including HIV

          -  Patients with clinically significant cardiovascular, renal, hepatic, endocrine
             disease, cancer, Type I diabetes

          -  Patients who are pregnant or currently breast-feeding mother

          -  Patients who were enrolled in any other clinical trials within the past 30 days

          -  Patients who had been administered with oriental medicine, glucosamine and
             chondroitin within 14 days of baseline visit

          -  Patients who had been administered with immunosuppressants and antirheumatic drugs
             within the past 3 months

          -  Patients who had skin disease around target knee

          -  History of infection within the past 3 months

          -  History of surgery within the past 6 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Gu Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Su Hee Kyung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chul Won Ha, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myung Chul Lee, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yong In, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea Seoul ST. Mary's Hospita</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seong Il Bin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seong Do Cho, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ulsan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jae Doo Yoo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ewha Womans University Mokdong</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myung Gu Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ju Hong Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ui Seong Choi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungbuk National University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chung Hyeok Choi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanyang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yeo-Myoeng Park, MS</last_name>
    <phone>82-02-3677-4187</phone>
    <phone_ext>4187</phone_ext>
    <email>paoliming@kolon.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jung-jong Cho, MS</last_name>
    <phone>82-02-3677-4153</phone>
    <phone_ext>4153</phone_ext>
    <email>jjcho@kolon.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju</city>
        <zip>361-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ui Seong Choi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyungpook National Univ. Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Su Hee Kyung, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Myung Gu Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju-si</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ju Hong Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yong In, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University Seoul Paik Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>100-032</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jin Gu Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hanyang University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>133-791</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chung Hyeok Choi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>158-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jae Doo Yoo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chul Won Ha, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Myung Chul Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASAN Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Seong Il Bin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <zip>682-714</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Seong Do Cho, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>March 5, 2014</lastchanged_date>
  <firstreceived_date>February 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chondrocyte cells, Osteoarthritis, gene therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
